Atopic Dermatology Quiz Challenge

NO PURCHASE NECESSARY. Void where prohibited. See Official Rules here for complete details. Odds of winning depend on the number of eligible entries received. Sponsor: MultiMedia Medical, LLC.

Question Title

1. Name (Required.)

Question Title

2. Email Address (Required.)

Question Title

3. Which of the following best describes the pathophysiology of atopic dermatitis (AD)? (Required.)

Overproduction of sebum leading to clogged pores

An imbalance of inflammatory cytokines, including IL-4 and IL-13, leading to barrier dysfunction and immune dysregulation

A fungal overgrowth that triggers immune hypersensitivity

A genetic disorder affecting collagen production

Question Title

4. What is a key characteristic of mild to moderate atopic dermatitis? (Required.)

Presence of widespread lichenification and fissuring

Red, inflamed, and pruritic skin with intermittent flare-ups

Pustular lesions with bacterial involvement

Non-pruritic lesions that heal without intervention

Question Title

5. Which of the following topical treatments is a PDE4 inhibitor approved for mild to moderate atopic dermatitis in patients aged 6 years and older? (Required.)

Crisaborole

Tacrolimus

Roflumilast

Pimecrolimus

Question Title

6. What role does PDE4 inhibition play in atopic dermatitis treatment? (Required.)

It directly increases collagen production for skin repair

It reduces inflammatory cytokines such as TNF-α, IL-4, and IL-13

It suppresses histamine release from mast cells

It eliminates Staphylococcus aureus colonization on the skin

Question Title

7. Which of the following is NOT a common comorbidity associated with atopic dermatitis? (Required.)

Asthma

Allergic rhinitis

Hypertension

Food allergies

Question Title

8. Which patient group is at the highest risk for developing atopic dermatitis? (Required.)

Adults over 50

Infants and young children

Postmenopausal women

Patients with a history of basal cell carcinoma

Question Title

9. In patients with atopic dermatitis, why is maintaining the skin barrier crucial? (Required.)

It prevents excessive sebum production

It reduces epidermal water loss and protects against allergens, irritants, and microbial invasion

It increases skin cell turnover to prevent hyperpigmentation

It enhances absorption of systemic medications

Question Title

10. What is a key benefit of ZORYVE (roflumilast) in the treatment of atopic dermatitis? (Required.)

It is a systemic therapy that targets the immune system

It provides rapid itch relief and reduces inflammation through PDE4 inhibition

It directly eliminates bacterial infections associated with AD

It is a corticosteroid that suppresses immune activity

Question Title

11. What is a common trigger for atopic dermatitis flare-ups? (Required.)

Sun exposure

High-fat diet

Emotional stress and allergens

Excessive sweating without hydration

Question Title

12. Which of the following is a key goal of atopic dermatitis management? (Required.)

Completely eliminate all triggers

Cure the condition with long-term antibiotic therapy

Reduce inflammation, restore the skin barrier, and minimize flare-ups

Use systemic steroids as first-line therapy

Atopic Dermatology Quiz Challenge

Question Title

* 1. Name (Required.)

Question Title

* 2. Email Address (Required.)

Question Title

* 3. Which of the following best describes the pathophysiology of atopic dermatitis (AD)? (Required.)

Question Title

* 4. What is a key characteristic of mild to moderate atopic dermatitis? (Required.)

Question Title

* 5. Which of the following topical treatments is a PDE4 inhibitor approved for mild to moderate atopic dermatitis in patients aged 6 years and older? (Required.)

Question Title

* 6. What role does PDE4 inhibition play in atopic dermatitis treatment? (Required.)

Question Title

* 7. Which of the following is NOT a common comorbidity associated with atopic dermatitis? (Required.)

Question Title

* 8. Which patient group is at the highest risk for developing atopic dermatitis? (Required.)

Question Title

* 9. In patients with atopic dermatitis, why is maintaining the skin barrier crucial? (Required.)

Question Title

* 10. What is a key benefit of ZORYVE (roflumilast) in the treatment of atopic dermatitis? (Required.)

Question Title

* 11. What is a common trigger for atopic dermatitis flare-ups? (Required.)

Question Title

* 12. Which of the following is a key goal of atopic dermatitis management? (Required.)

1. Name (Required.)

2. Email Address (Required.)

3. Which of the following best describes the pathophysiology of atopic dermatitis (AD)? (Required.)

4. What is a key characteristic of mild to moderate atopic dermatitis? (Required.)

5. Which of the following topical treatments is a PDE4 inhibitor approved for mild to moderate atopic dermatitis in patients aged 6 years and older? (Required.)

6. What role does PDE4 inhibition play in atopic dermatitis treatment? (Required.)

7. Which of the following is NOT a common comorbidity associated with atopic dermatitis? (Required.)

8. Which patient group is at the highest risk for developing atopic dermatitis? (Required.)

9. In patients with atopic dermatitis, why is maintaining the skin barrier crucial? (Required.)

10. What is a key benefit of ZORYVE (roflumilast) in the treatment of atopic dermatitis? (Required.)

11. What is a common trigger for atopic dermatitis flare-ups? (Required.)

12. Which of the following is a key goal of atopic dermatitis management? (Required.)